SCHEDULE 13G/A: BlackRock, Inc. Discloses 16.6% Stake in Protagonist Therapeutics
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, reporting a 16.6% beneficial ownership stake in Protagonist Therapeutics, Inc. as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 9,884,617 shares of Protagonist Therapeutics, Inc. common stock.
- This represents 16.6% of the total outstanding common stock of Protagonist Therapeutics, Inc.
- BlackRock, Inc. holds sole voting power over 9,796,642 shares and sole dispositive power over 9,884,617 shares.
- The filing is an Amendment No. 5 to Schedule 13G, indicating an update to previous ownership disclosures.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- iShares Core S & P Small-Cap ETF, a subsidiary of BlackRock, Inc., is noted as having an interest of more than 5% in Protagonist Therapeutics, Inc. common stock.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing disclosing a significant passive ownership stake by a major institutional investor. It contains no negative news or red flags, indicating a stable, albeit passive, investment. The high percentage of ownership by BlackRock could be seen as a positive signal of institutional confidence.
Positives
- BlackRock, Inc.'s significant 16.6% stake indicates a substantial institutional investment in Protagonist Therapeutics, Inc.
- The filing confirms the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist intent to influence control.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Protagonist Therapeutics, Inc.'s future performance or BlackRock's future investment intentions beyond the current ownership disclosure.
Management Comments
- "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing is a routine disclosure of a significant institutional ownership stake in a biotechnology company. Large asset managers like BlackRock frequently hold substantial positions across various industries as part of their diversified investment strategies, reflecting their role in passive and active fund management. The filing itself does not provide specific industry trends but highlights the continued institutional interest in the pharmaceutical/biotechnology sector, represented by Protagonist Therapeutics, Inc.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, effective January 21, 2025, revoking a previous one from April 30, 2023. This grants specific individuals the authority to execute and file documents related to ownership or control-person reporting requirements on behalf of BlackRock and its subsidiaries. | 2025-01-21 | This is an internal administrative update for BlackRock, Inc. to streamline its regulatory filing processes, with no direct impact on Protagonist Therapeutics, Inc.'s corporate governance or operations. |
Related Party Transactions
- iShares Core S & P Small-Cap ETF, a subsidiary of BlackRock, Inc., is noted as having an interest of more than 5% in the common stock of Protagonist Therapeutics, Inc., representing an internal relationship within BlackRock's managed funds.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially offering a degree of stability or confidence due to BlackRock's passive investment.
- Company Management (Protagonist Therapeutics): Awareness of a large, passive institutional investor, which typically does not seek to influence control.
Next Steps
- BlackRock, Inc. will continue to file amendments to Schedule 13G if there are material changes to its beneficial ownership of Protagonist Therapeutics, Inc. shares.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney, which has been revoked. |
| 2024-12-31 | Date of event which requires the filing of this statement (reporting period end). |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-02-05 | Date of signature for the Schedule 13G filing. |
Keywords
Protagonist Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, PTGX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.